Stock Events

Stock Events

Clearside Biomedical 

$0.3
0
+$0.03+12.75% Thursday 19:58

Statistics

Day High
0.3
Day Low
0.19
52W High
14.1
52W Low
0.19
Volume
9
Avg. Volume
26,091
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14MayExpected
Q3 2025
Next
-1.35
-1.11
-0.86
-0.62
Expected EPS
-1.35
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CLSDQ. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
EyePoint
EYPT
Mkt Cap1.06B
EyePoint Pharmaceuticals focuses on developing treatments for eye diseases, directly competing with Clearside's ocular therapies.
Bausch Health Companies
BHC
Mkt Cap2.62B
Bausch Health Companies, through its eye health division, competes in developing treatments for various eye conditions.
Novartis
NVS
Mkt Cap237.61B
Novartis offers a broad portfolio of drugs, including treatments for eye diseases, competing on a global scale.
Regenxbio
RGNX
Mkt Cap645.07M
REGENXBIO's focus on AAV gene therapies for retinal diseases puts it in direct competition with Clearside's eye disease treatments.
Ocular Therapeutix
OCUL
Mkt Cap2.47B
Ocular Therapeutix develops innovative therapies for eye diseases, competing in the ocular drug delivery space.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline, with its broad pharmaceutical portfolio, includes treatments for eye conditions, making it a competitor in the broader pharmaceutical market.

About

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Show more...
CEO
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
Employees
32
Country
US
ISIN
US1850632035

Listings

OTC Link
US
CLSDQ

0 Comments

Share your thoughts

FAQ

What is Clearside Biomedical stock price today?▼
The current price of CLSDQ is $0.3 USD — it has increased by +12.75% in the past 24 hours. Watch Clearside Biomedical stock price performance more closely on the chart.
What is Clearside Biomedical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Clearside Biomedical stocks are traded under the ticker CLSDQ.
When is the next Clearside Biomedical earnings date?▼
Clearside Biomedical is going to release the next earnings report on May 14, 2026.
How many employees does Clearside Biomedical have?▼
As of April 04, 2026, the company has 32 employees.
In which sector is Clearside Biomedical located?▼
Clearside Biomedical operates in the Health Care sector.
When did Clearside Biomedical complete a stock split?▼
Clearside Biomedical has not had any recent stock splits.
Where is Clearside Biomedical headquartered?▼
Clearside Biomedical is headquartered in Alpharetta, US.